Peroxisome proliferator-activated receptor α as a novel therapeutic target for schizophrenia

过氧化物酶体增殖激活受体α作为精神分裂症的新治疗靶点

阅读:6
作者:Yuina Wada, Motoko Maekawa, Tetsuo Ohnishi, Shabeesh Balan, Shigeru Matsuoka, Kazuya Iwamoto, Yoshimi Iwayama, Hisako Ohba, Akiko Watanabe, Yasuko Hisano, Yayoi Nozaki, Tomoko Toyota, Tomomi Shimogori, Masanari Itokawa, Tetsuyuki Kobayashi, Takeo Yoshikawa

Background

The pathophysiology of schizophrenia, a major psychiatric disorder, remains elusive. In this study, the role of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor (RXR) families, belonging to the ligand-activated nuclear receptor superfamily, in schizophrenia, was analyzed.

Methods

The PPAR/RXR family genes were screened by exploiting molecular inversion probe (MIP)-based targeted next-generation sequencing (NGS) using the samples of 1,200 Japanese patients with schizophrenia. The

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。